The recent approval by the European Medicines Agency for a new treatment for sleeping sickness marks a significant advancement in tackling this neglected disease, particularly in African countries where it is endemic. This new drug is particularly noteworthy as it only requires a single application to cure the majority of patients, a stark contrast to the previous treatment methods which involved arsenic-based injections that often had deadly side effects. Approximately one in twenty patients used to die from these treatments, highlighting the desperate need for safer alternatives in managing this disease.

Sleeping sickness, or African trypanosomiasis, has historically been associated with severe stigma, as individuals affected by the disease often exhibited personality changes, aggression, and sleep disturbances. As a result, patients were frequently misidentified as having mental health issues or being possessed, exacerbating their suffering and leading to societal exclusion. As Luis Pizarro from the Drugs for Neglected Diseases initiative points out, the disease symbolizes broader issues of neglected public health concerns that require urgent attention amidst ongoing cuts in global development aid.

The introduction of this drug into affected regions not only promises to improve health outcomes for many but also raises questions about the future of funding and support for healthcare initiatives in these regions. With development aid being reduced globally, ongoing support will be critical in ensuring that such advancements reach those in need effectively, allowing for a potential shift in the narrative surrounding neglected diseases and the historic neglect faced by their patients.